Opinion of the Transparency Council – carbamazepine
At its meeting on 14 April 2025, the Transparency Council adopted opinion No. 63/2025 on the inclusion of medicinal products containing the active substance carbamazepine in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics, i.e. neuralgia in cases other than those specified in the SPC; neuropathic pain in cases other than those specified in the SPC